Skip to main content

Table 5 Univariate analysis of pCR according to breast cancer molecular expressions and TILs

From: Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial

Group pCR Covariate P value
   Molecular subtypes  
HR+/HER2- HR+/HER2+ HR-/HER2+ TNBC
Intervention   n = 9 n = 12 n = 2 n = 2  
  + 0 7 (58.3) 0 1 (50.0) 0.014
- 9 (100.0) 5 (41.7) 2 (100.0) 1 (50.0)
Control   n = 12 n = 11 n = 2 n = 2  
  + 1 (8.3) 5 (45.5) 1 (50.0) 1 (50.0) 0.125
- 11 (91.7) 6 (54.5) 1 (50.0) 1 (50.0)
Total   n = 21 n = 23 n = 4 n = 4  
  + 1 (4.8) 12 (52.2) 1 (25.0) 2 (50.0) 0.002
- 20 (95.2) 11 (47.8) 3 (75.0) 2 (50.0)
   ER Status  
positive negative
Intervention   n = 21 n = 4  
  + 7 (33.3) 1 (25.0) 1.00
- 14 (66.7) 3 (75.0)
Control   n = 23 n = 4  
  + 6 (26.1) 2 (50.0) 0.558
- 17 (73.9) 2 (50.0)
Total   n = 44 n = 8  
  + 13 (29.5) 3 (37.5) 0.689
- 31 (70.5) 5 (62.5)
   PR Status  
positive negative  
Intervention   n = 14 n = 11  
  + 4 (28.6) 4 (36.3) 1.00
- 10 (71.4) 7 (63.6)
Control   n = 19 n = 8  
  + 5 (26.3) 3 (37.5) 0.658
- 14 (73.7) 5 (62.5)
Total   n = 33 n = 19  
  + 9 (27.3) 7 (36.8) 0.472
- 24 (72.7) 12 (63.1)
   HER2 Status  
positive negative  
Intervention   n = 10 n = 15  
  + 5 (50.0) 3 (20.0) 0.194
- 5 (50.0) 12 (80.0)
Control   n = 8 n = 19  
  + 5 (62.5) 3 (15.8) 0.027
- 3 (37.5) 16 (84.2)
Total   n = 18 n = 34  
  + 10 (55.5) 6 (17.6) 0.005
- 8 (44.4) 28 (82.3)
   ki67 status  
positive negative  
Intervention   n = 19 n = 6  
  + 8 (42.1) 0 (0) 0.129
- 11 (57.9) 6 (100.0)
Control   n = 15 n = 12  
  + 6 (40.0) 2 (16.7) 0.236
- 9 (60.0) 10 (83.3)
Total   n = 34 n = 18  
  + 14 (41.2) 2 (11.1) 0.025
- 20 (58.8) 16 (88.9)
   TILS  
positive negative  
Intervention   n = 10 n = 15  
  + 6 (60.0) 2 (13.3) 0.028
- 4 (40.0) 13 (86.7)
Control   n = 13 n = 14  
  + 5 (38.5) 3 (21.4) 0.420
- 8 (61.5) 11 (78.6)
Total   n = 23 n = 29  
  + 11 (47.8) 5 (17.2) 0.018
- 12 (52.2) 24 (82.7)
  1. TNBC triple negative breast cancer, pCR pathologic complete response, ER estrogen receptor, PR progesterone receptor, TILs Tumor-infiltrating lymphocytes
  2. Note: + stands for pCR, - stands for non-pCR